Introducing Time in an Industrial Application of Model-Checking

L. V. D. Berg,P. Strooper,Kirsten Winter

DOI: https://doi.org/10.1007/978-3-540-79707-4_6

2007-07-01

Abstract:

What problem does this paper attempt to address?

Precision Medicine Approaches in Oncology: Current Trends and Future Directions

Andi Asrina

DOI: https://doi.org/10.60079/ahr.v2i1.370

2024-02-28

Abstract:Purpose: This study explores the transformative potential of precision medicine in oncology, highlighting advancements in targeted therapies and immunotherapies and addressing practical and theoretical challenges in clinical implementation. Research Design and Methodology: Utilizing a mixed-methods design, the study integrates quantitative data from a cross-sectional survey of oncologists and qualitative insights from in-depth interviews with key stakeholders. Advanced bioinformatics tools and multi-omics data (genomics, proteomics, and transcriptomics) are analyzed to identify novel therapeutic targets and biomarkers. Findings and Discussion: The findings show that precision medicine improves patient outcomes by tailoring treatments to tumors' genetic and molecular profiles. Targeted therapies, such as tyrosine kinase and epidermal growth factor receptor inhibitors, exhibit enhanced efficacy and reduced toxicity. Immunotherapy, remarkably immune checkpoint inhibitors, demonstrates significant promise but shows variability in patient responses, underscoring the need for predictive biomarkers. Integrating multi-omics data provides a comprehensive understanding of cancer biology and new therapeutic targets. Challenges include high costs, the need for robust bioinformatics infrastructure, and ethical considerations. Implications: This study underscores the need for investment in bioinformatics infrastructure, standardized guidelines, and training for healthcare providers. Policymakers should develop strategies to lower genetic testing costs and ensure equitable access to precision medicine. Future research should focus on cost-effective genomic testing methods, combination therapies to overcome resistance, and expanding studies to diverse populations to enhance the applicability and accessibility of precision medicine benefits.

Medicine,Biology
Emergence of Precision Medicine Within Neurological Surgery: Promise and Opportunity

Rachel E Yan,Jeffrey P Greenfield

DOI: https://doi.org/10.1016/j.wneu.2024.06.143

Abstract:Within neurosurgery, it has always been important to individualize patient care. In recent years, however, technological advances have brought a new dimension to personalized care as developing methods, including next-generation sequencing, have enabled us to molecularly profile pathologies with increasing scale and resolution. In this review, the authors discuss the history and advances in precision medicine and neurosurgery, focusing both on neuro-oncology, as well as its extension to other neurosurgical subspecialties. They highlight the important roles of neurosurgeons in past work and future work, with the extension of tissue collection and precision medicine principles to additional sample types and disease indications.
Problems, challenges and promises: perspectives on precision medicine

David J Duffy,David J. Duffy

DOI: https://doi.org/10.1093/bib/bbv060

IF: 9.5

2015-08-05

Briefings in Bioinformatics

Abstract:The 'precision medicine (systems medicine)' concept promises to achieve a shift to future healthcare systems with a more proactive and predictive approach to medicine, where the emphasis is on disease prevention rather than the treatment of symptoms. The individualization of treatment for each patient will be at the centre of this approach, with all of a patient's medical data being computationally integrated and accessible. Precision medicine is being rapidly embraced by biomedical researchers, pioneering clinicians and scientific funding programmes in both the European Union (EU) and USA. Precision medicine is a key component of both Horizon 2020 (the EU Framework Programme for Research and Innovation) and the White House's Precision Medicine Initiative. Precision medicine promises to revolutionize patient care and treatment decisions. However, the participants in precision medicine are faced with a considerable central challenge. Greater volumes of data from a wider variety of sources are being generated and analysed than ever before; yet, this heterogeneous information must be integrated and incorporated into personalized predictive models, the output of which must be intelligible to non-computationally trained clinicians. Drawing primarily from the field of 'oncology', this article will introduce key concepts and challenges of precision medicine and some of the approaches currently being implemented to overcome these challenges. Finally, this article also covers the criticisms of precision medicine overpromising on its potential to transform patient care.

biochemical research methods,mathematical & computational biology
Precision Oncology: Evolving Clinical Trials across Tumor Types

I-Wen Song,Henry Hiep Vo,Ying-Shiuan Chen,Mehmet A. Baysal,Michael Kahle,Amber Johnson,Apostolia M. Tsimberidou

DOI: https://doi.org/10.3390/cancers15071967

2023-03-26

Cancers

Abstract:Advances in molecular technologies and targeted therapeutics have accelerated the implementation of precision oncology, resulting in improved clinical outcomes in selected patients. The use of next-generation sequencing and assessments of immune and other biomarkers helps optimize patient treatment selection. In this review, selected precision oncology trials including the IMPACT, SHIVA, IMPACT2, NCI-MPACT, TAPUR, DRUP, and NCI-MATCH studies are summarized, and their challenges and opportunities are discussed. Brief summaries of the new ComboMATCH, MyeloMATCH, and iMATCH studies, which follow the example of NCI-MATCH, are also included. Despite the progress made, precision oncology is inaccessible to many patients with cancer. Some patients' tumors may not respond to these treatments, owing to the complexity of carcinogenesis, the use of ineffective therapies, or unknown mechanisms of tumor resistance to treatment. The implementation of artificial intelligence, machine learning, and bioinformatic analyses of complex multi-omic data may improve the accuracy of tumor characterization, and if used strategically with caution, may accelerate the implementation of precision medicine. Clinical trials in precision oncology continue to evolve, improving outcomes and expediting the identification of curative strategies for patients with cancer. Despite the existing challenges, significant progress has been made in the past twenty years, demonstrating the benefit of precision oncology in many patients with advanced cancer.

oncology
Precision oncology: current and future platforms for treatment selection

Xinran Tang,Michael F Berger,David B Solit

DOI: https://doi.org/10.1016/j.trecan.2024.06.009

Abstract:Genomic profiling of hundreds of cancer-associated genes is now a component of routine cancer care. DNA sequencing can identify mutations, mutational signatures, and structural alterations predictive of therapy response and assess for heritable cancer risk, but it has been less useful for identifying predictive biomarkers of sensitivity to cytotoxic chemotherapies, antibody drug conjugates, and immunotherapies. The clinical adoption of molecular profiling platforms such as RNA sequencing better suited to identifying those patients most likely to respond to immunotherapies and drug combinations will be critical to expanding the benefits of precision oncology. This review discusses the potential advantages of innovative molecular and functional profiling platforms designed to replace or complement targeted DNA sequencing and the major hurdles to their clinical adoption.
Precision medicine in medical oncology: hope, disappointment and reality

Marie Bartoušková,Bohuslav Melichar

DOI: https://doi.org/10.1515/cclm-2020-0231

2020-04-09

Clinical Chemistry and Laboratory Medicine (CCLM)

Abstract:Abstract During the past 20 years, targeted therapy based on the understanding of tumor biology has been complementing or even replacing cytotoxic agents that have dominated pharmacotherapy of cancer since the conception of medical oncology. Unfortunately, the fact that targeted therapies with potential to induce cure or at least substantially prolong survival are still not available for many common solid tumors results in skepticism or even nihilism. On the one hand, biomarker research is not keeping pace with the introduction of new agents, while on the other hand, effective drugs are still not available for many potential molecular targets associated with malignant transformation and tumor progression. However, targeted therapies have already transformed the natural history and clinical outcomes not only in patients with rare malignancies like gastrointestinal stromal tumor but also with many common tumors, e.g. breast cancer, malignant melanoma, non-small cell lung cancer or renal cell carcinoma. For further advances, a multidisciplinary effort is indispensible that should, above all, involve the collaboration of medical oncology and laboratory medicine.
Precision Oncology: 2024 in Review

Matteo Repetto,Nicole Fernandez,Alexander Drilon,Debyani Chakravarty

DOI: https://doi.org/10.1158/2159-8290.cd-24-1476

IF: 28.2

2024-12-04

Cancer Discovery

Abstract:Summary: This article discusses the specific advances made in precision oncology in 2024. We comment on the evolving nature of predictive molecular events used to select patients who will most benefit clinically from treatment. We also discuss advances in the development of strategic treatment regimens for combination therapies, rational drug design of small-molecule inhibitors, and structurally informed drug repurposing.

oncology
Molecular Profiling-Based Precision Medicine In Cancer: A Review Of Current Evidence And Challenges

Qi Zhang,Qihan Fu,Xueli Bai,Tingbo Liang

DOI: https://doi.org/10.3389/fonc.2020.532403

IF: 4.7

2020-01-01

Frontiers in Oncology

Abstract:Matched therapy based on next-generation sequencing is now a part of routine care to guide the treatment of patients with advanced solid tumors. However, whether and to what extent patients can benefit from this strategy on a large scale remains uncertain. In the past decade, several clinical studies were performed in this field, among which only one was a randomized trial. We reviewed the literature on this topic and summarize the existing data about the efficacy of this treatment strategy. Currently, the evidence is promising but not solid. Multiple ongoing trials are also summarized. We also discuss the limitations of this treatment strategy and certain unsolved important problems, including how to select the sample and target level, how to interpret the results, and the problem of drug accessibility. All these issues should receive more attention in future clinical trial design and the application of target therapy in cancer treatment.
Delivering precision oncology to patients with cancer

Joaquin Mateo,Lotte Steuten,Philippe Aftimos,Fabrice André,Mark Davies,Elena Garralda,Jan Geissler,Don Husereau,Iciar Martinez-Lopez,Nicola Normanno,Jorge S. Reis-Filho,Stephen Stefani,David M. Thomas,C. Benedikt Westphalen,Emile Voest

DOI: https://doi.org/10.1038/s41591-022-01717-2

IF: 82.9

2022-04-01

Nature Medicine

Abstract:With the increasing use of genomic profiling for diagnosis and therapy guidance in many tumor types, precision oncology is rapidly reshaping cancer care. However, the current trajectory of drug development in oncology results in a paradox: if patients cannot access advanced diagnostics, we may be developing drugs that will reach few patients. In this Perspective, we outline the major challenges to the implementation of precision oncology and discuss critical steps toward resolving these, including facilitation of equal access to genomics tests, ensuring that clinical studies provide robust evidence for new drugs and technologies, enabling physicians to interpret genomics data, and empowering patients toward shared decision-making. A multi-stakeholder approach to evidence generation, value assessment, and healthcare delivery is necessary to translate advances in precision oncology into benefits for patients with cancer globally.

biochemistry & molecular biology,cell biology,medicine, research & experimental
Advances in Precision Medicine Approaches for Colorectal Cancer: From Molecular Profiling to Targeted Therapies

Neelakanta Sarvashiva Kiran,Chandrashekar Yashaswini,Rahul Maheshwari,Sankha Bhattacharya,Bhupendra G Prajapati

DOI: https://doi.org/10.1021/acsptsci.4c00008

2024-03-19

Abstract:Precision medicine is transforming colorectal cancer treatment through the integration of advanced technologies and biomarkers, enhancing personalized and effective disease management. Identification of key driver mutations and molecular profiling have deepened our comprehension of the genetic alterations in colorectal cancer, facilitating targeted therapy and immunotherapy selection. Biomarkers such as microsatellite instability (MSI) and DNA mismatch repair deficiency (dMMR) guide treatment decisions, opening avenues for immunotherapy. Emerging technologies such as liquid biopsies, artificial intelligence, and machine learning promise to revolutionize early detection, monitoring, and treatment selection in precision medicine. Despite these advancements, ethical and regulatory challenges, including equitable access and data privacy, emphasize the importance of responsible implementation. The dynamic nature of colorectal cancer, with its tumor heterogeneity and clonal evolution, underscores the necessity for adaptive and personalized treatment strategies. The future of precision medicine in colorectal cancer lies in its potential to enhance patient care, clinical outcomes, and our understanding of this intricate disease, marked by ongoing evolution in the field. The current reviews focus on providing in-depth knowledge on the various and diverse approaches utilized for precision medicine against colorectal cancer, at both molecular and biochemical levels.
Medical imaging in tumor precision medicine: opportunities and challenges

Jingjing XU,Yanbin TAN,Minming ZHANG

DOI: https://doi.org/10.3785/j.issn.1008-9292.2017.10.01

2017-01-01

Abstract:Tumor precision medicine is an emerging approach for tumor diagnosis, treatment and prevention,which takes account of individual variability of environment, lifestyle and genetic information. Tumor precision medicine is built up on the medical imaging innovations developed during the past decades, including the new hardware, new imaging agents, standardized protocols, image analysis and multimodal imaging fusion technology. Also the development of automated and reproducible analysis algorithm has extracted large amount of information from image-based features. With the continuous development and mining of tumor clinical and imaging databases, the radiogenomics, radiomics and artificial intelligence have been flourishing. Therefore, these new technological advances bring new opportunities and challenges to the application of imaging in tumor precision medicine.
Evolving landscape of tumor molecular profiling for personalized cancer therapy: a comprehensive review

Nicholas Li-Xun Syn,Wei-Peng Yong,Boon-Cher Goh,Soo-Chin Lee

DOI: https://doi.org/10.1080/17425255.2016.1196187

2016-06-13

Abstract:INTRODUCTION: Tumour molecular profiling has been at the crossroads of large-scale integrative genomic studies and major clinical trials over the past 5 years and has provided roadmaps for better disease stratification and therapeutic management.AREAS COVERED: We review the landscape of precision oncology trials in Asia, Europe and the United States, and emerging insights gained from recently reported studies such as the SHIVA and CUSTOM trials. Changes in the molecular portraits of human cancers and the immune contexture of the tumor microenvironment during treatment may predict the course of tumor progression, including the development of treatment resistance. 'Liquid biopsy' approaches that harness circulating tumor cells, cell-free DNA and exosomes may provide a non-invasive means of monitoring the parent tumor in real-time. Several molecular signatures are being evaluated as biomarkers for emerging immunologic approaches, such as the mismatch-repair deficiency status and nonsynonymous mutation burden in anti-PD-1 immune checkpoint blockade. Finally, we review the current actionability and future clinical impact of multigene panel and next-generation sequencing (NGS)-based profiling.EXPERT OPINION: In the future, molecular profiling may help to fulfill unmet needs for predictive biomarkers in novel immunotherapeutic approaches, while ongoing precision trials are laying the foundations for clinical uptake of NGS testing.

pharmacology & pharmacy,biochemistry & molecular biology,toxicology
The progress and challenges of precision oncology

Lun-xiu QIN,Hao-ting SUN,Lu-yu YANG

DOI: https://doi.org/10.3969/j.issn.1672-8467.2017.06.015

2017-01-01

Abstract:Precision oncology is applying established clinic-pathological indexes with molecular profiling to create diagnostic,prognostic,and therapeutic strategies precisely tailor to each patient's requirements.It includes precision prevention (cancer risk detection and prophylactic intervention),precision diagnosis (early detection and diagnosis,molecular classification),and precision treatment (molecular targeted therapies,predicting and monitoring treatment response and precision surgery based on the combination of visual,cytology,pathologic review,as well as molecular profiling assessments).Understanding of cancer and clinical decision making from the molecular level is necessary in era of precision oncology.Many challenges,including the heterogeneity and dynamic evolution of cancer cells,few understanding about cancer biology,pairing the massive genomic data with inaccurate clinical information,limited sensitive drugs and unexplained resistance,insufficient cancer biomarkers for precision diagnosis and treatment,have to be overcome before it can be clinical routines.
Advances in Targeted Therapy for Cancer: Precision Medicine Approaches

,Beatrice Brenda Asha

DOI: https://doi.org/10.59298/idosrjas/2024/9.2.636700

2024-08-13

Abstract:Advances in targeted therapy and precision medicine have revolutionized cancer treatment by focusing on therapies that specifically address the molecular and genetic abnormalities driving tumor growth. This review explores the mechanisms underlying targeted therapies, including small molecule inhibitors, monoclonal antibodies, antibody-drug conjugates, and gene editing technologies. The integration of precision medicine, which tailors treatments based on detailed molecular profiling of tumors, has led to significant breakthroughs such as next-generation inhibitors, improved antibody-drug conjugates, and innovative RNA-based therapies. Despite these advances, challenges such as resistance mechanisms, adverse effects, and high costs remain. Future directions include the incorporation of artificial intelligence for drug discovery, expansion of precision oncology, and development of novel therapeutic modalities. A comprehensive literature review and expert consultation to synthesize current advancements and identify future research opportunities was utilised in writing this review article. This article aims to provide insights into how targeted therapy and precision medicine are transforming cancer treatment and outlines the path forward for achieving more effective and personalized cancer care. Keywords: Targeted Therapy, Precision Medicine, Genomic Profiling, Antibody-Drug Conjugates (ADCs), Artificial Intelligence.
Bioinformatic Challenges Detecting Genetic Variation in Precision Medicine Programs

Matt A Field

DOI: https://doi.org/10.3389/fmed.2022.806696

2022-04-08

Abstract:Precision medicine programs to identify clinically relevant genetic variation have been revolutionized by access to increasingly affordable high-throughput sequencing technologies. A decade of continual drops in per-base sequencing costs means it is now feasible to sequence an individual patient genome and interrogate all classes of genetic variation for < $1,000 USD. However, while advances in these technologies have greatly simplified the ability to obtain patient sequence information, the timely analysis and interpretation of variant information remains a challenge for the rollout of large-scale precision medicine programs. This review will examine the challenges and potential solutions that exist in identifying predictive genetic biomarkers and pharmacogenetic variants in a patient and discuss the larger bioinformatic challenges likely to emerge in the future. It will examine how both software and hardware development are aiming to overcome issues in short read mapping, variant detection and variant interpretation. It will discuss the current state of the art for genetic disease and the remaining challenges to overcome for complex disease. Success across all types of disease will require novel statistical models and software in order to ensure precision medicine programs realize their full potential now and into the future.
Epistemology, Ethics, and Progress in Precision Medicine

Spencer Phillips Hey,Brianna Barsanti-Innes

DOI: https://doi.org/10.1353/pbm.2016.0026

Abstract:The emerging paradigm of precision medicine strives to leverage the tools of molecular biology to prospectively tailor treatments to the individual patient. Fundamental to the success of this movement is the discovery and validation of "predictive biomarkers," which are properties of a patient's biological specimens that can be assayed in advance of therapy to inform the treatment decision. Unfortunately, research into biomarkers and diagnostics for precision medicine has fallen well short of expectations. In this essay, we examine the portfolio of research activities into the excision repair cross complement group 1 (ERCC1) gene as a predictive biomarker for precision lung cancer therapy as a case study in elucidating the epistemological and ethical obstacles to developing new precision medicines.
Precision Medicine: Steps along the Road to Combat Human Cancer

Samuel F. Nassar,Khadir Raddassi,Baljit Ubhi,Joseph Doktorski,Ahmad Abulaban

DOI: https://doi.org/10.3390/cells9092056

IF: 6

2020-09-09

Cells

Abstract:The diagnosis and treatment of diseases such as cancer is becoming more accurate and specialized with the advent of precision medicine techniques, research and treatments. Reaching down to the cellular and even sub-cellular level, diagnostic tests can pinpoint specific, individual information from each patient, and guide providers to a more accurate plan of treatment. With this advanced knowledge, researchers and providers can better gauge the effectiveness of drugs, radiation, and other therapies, which is bound to lead to a more accurate, if not more positive, prognosis. As precision medicine becomes more established, new techniques, equipment, materials and testing methods will be required. Herein, we will examine the recent innovations in assays, devices and software, along with next generation sequencing in genomics diagnostics which are in use or are being developed for personalized medicine. So as to avoid duplication and produce the fullest possible benefit, all involved must be strongly encouraged to collaborate, across national borders, public and private sectors, science, medicine and academia alike. In this paper we will offer recommendations for tools, research and development, along with ideas for implementation. We plan to begin with discussion of the lessons learned to date, and the current research on pharmacogenomics. Given the steady stream of advances in imaging mass spectrometry and nanoLC-MS/MS, and use of genomic, proteomic and metabolomics biomarkers to distinguish healthy tissue from diseased cells, there is great potential to utilize pharmacogenomics to tailor a drug or drugs to a particular cohort of patients. Such efforts very well may bring increased hope for small groups of non-responders and those who have demonstrated adverse reactions to current treatments.

cell biology
Molecular tumour boards - current and future considerations for precision oncology

Apostolia M Tsimberidou,Michael Kahle,Henry Hiep Vo,Mehmet A Baysal,Amber Johnson,Funda Meric-Bernstam

DOI: https://doi.org/10.1038/s41571-023-00824-4

Abstract:Over the past 15 years, rapid progress has been made in developmental therapeutics, especially regarding the use of matched targeted therapies against specific oncogenic molecular alterations across cancer types. Molecular tumour boards (MTBs) are panels of expert physicians, scientists, health-care providers and patient advocates who review and interpret molecular-profiling results for individual patients with cancer and match each patient to available therapies, which can include investigational drugs. Interpretation of the molecular alterations found in each patient is a complicated task that requires an understanding of their contextual functional effects and their correlations with sensitivity or resistance to specific treatments. The criteria for determining the actionability of molecular alterations and selecting matched treatments are constantly evolving. Therefore, MTBs have an increasingly necessary role in optimizing the allocation of biomarker-directed therapies and the implementation of precision oncology. Ultimately, increased MTB availability, accessibility and performance are likely to improve patient care. The challenges faced by MTBs are increasing, owing to the plethora of identifiable molecular alterations and immune markers in tumours of individual patients and their evolving clinical significance as more and more data on patient outcomes and results from clinical trials become available. Beyond next-generation sequencing, broader biomarker analyses can provide useful information. However, greater funding, resources and expertise are needed to ensure the sustainability of MTBs and expand their outreach to underserved populations. Harmonization between practice and policy will be required to optimally implement precision oncology. Herein, we discuss the evolving role of MTBs and current and future considerations for their use in precision oncology.
Improvement of clonality detection rate in multiple myeloma using fluorescent IgH PCR with different sets of primers.

V. Welterlin,A. Debecker,D. Tschieb,C. Zanetti,W. Lange,P. Hénon

DOI: https://doi.org/10.1089/152581600750062444

2000-12-01

Journal of Hematotherapy & Stem Cell Research

Abstract:The IgH rearrangement provides a useful marker of clonality in B-cell malignancies and amplification of this rearrangement is the method of choice to monitor the residual tumor cells in multiple myeloma (MM). The critical point of this analysis was the false-negative rate observed at diagnosis in patients presenting tumor cells well above the limit of detection. The aim of this study was therefore to increase the clonality detection rate by IgH polymerase chain reaction (PCR). Bone marrow DNA from 37 MM patients were analyzed at diagnosis. IgH PCR with agarose gel detection was performed between framework regions FR3 and FR1, both in combination with 5 different primers in FR4. Fluorescent IgH PCR with highly resolutive capillary electrophoresis was used to improve the detection and to size clonal PCR products. Sixty-two percent of the clonal rearrangements were initially detected with JHD primer specific to the JH segments 1,2,4,5. The use of JH3 and JH6 homologous primers increased the detection rate to 78%, whereas a consensus JH primer only reached 67% of positivity. The lowest detection rates were obtained with JHExt and JH3 with a detection of respectively 43 and 14%. However, three rearrangements were exclusively amplified by JHExt and two additional cases were detected by JH3. The combined use of primers yielded the best score with 89% of positivity. With Genescan analysis, two additional cases showed a monoclonal rearrangement improving the detection rate to 95%. The use of multiple sets of primers along with a highly sensitive genescan analysis makes possible the follow-up of minimal residual disease for most MM patients.
[Breast cancer research in the era of precision medicine].

H Y Yang,Y Z Jiang,Z M Shao

DOI: https://doi.org/10.3760/cma.j.issn.0253-3766.2016.06.001

2016-01-01

Abstract:Precision medicine is an emerging medical strategy that takes into account individual molecular variations of disease to guide accurate prevention and treatment.Tumor molecular markers closely related to aggressive behavior and treatment response will be identified by integrating clinical information and multiple-omics, and will be verified in well-designed clinical trials. Breast cancer is a highly heterogeneous disease. Its treatment based on molecular subtyping has achieved initial success. However, drug resistance and tumor heterogeneity are still major challenges. This review will focus on the recent progress and future prospects of clinical research on breast cancer in the era of precision medicine.

Introducing Time in an Industrial Application of Model-Checking

Precision Medicine Approaches in Oncology: Current Trends and Future Directions

Emergence of Precision Medicine Within Neurological Surgery: Promise and Opportunity

Problems, challenges and promises: perspectives on precision medicine

Precision Oncology: Evolving Clinical Trials across Tumor Types

Precision oncology: current and future platforms for treatment selection

Precision medicine in medical oncology: hope, disappointment and reality

Precision Oncology: 2024 in Review

Molecular Profiling-Based Precision Medicine In Cancer: A Review Of Current Evidence And Challenges

Delivering precision oncology to patients with cancer

Advances in Precision Medicine Approaches for Colorectal Cancer: From Molecular Profiling to Targeted Therapies

Medical imaging in tumor precision medicine: opportunities and challenges

Evolving landscape of tumor molecular profiling for personalized cancer therapy: a comprehensive review

The progress and challenges of precision oncology

Advances in Targeted Therapy for Cancer: Precision Medicine Approaches

Bioinformatic Challenges Detecting Genetic Variation in Precision Medicine Programs

Epistemology, Ethics, and Progress in Precision Medicine

Precision Medicine: Steps along the Road to Combat Human Cancer

Molecular tumour boards - current and future considerations for precision oncology

Improvement of clonality detection rate in multiple myeloma using fluorescent IgH PCR with different sets of primers.

[Breast cancer research in the era of precision medicine].